Business Wire

THALES

Share
Thales Revolutionises IoT "out-of-the-box" Connectivity to any Cellular Network Worldwide

The award winning* Cinterion® IoT Suite Connectivity Activation by Thales greatly simplifies and digitalises cellular connectivity and the daily operations of industrial IoT device manufacturers and service providers. Based on standard eSIM technology, the new solution eliminates the need for IoT service providers to setup and run complex eSIM Remote Subscription Provisioning (RSP) platforms. It uses a single IoT eSIM that works with whichever mobile operator is selected by the device manufacturer or IoT service provider. The solution also enables resilient device connectivity and lifecycle management over the multi-year life spans of industrial solutions thereby delivering a reduction in Total Cost of Ownership for customers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210608005041/en/

By 2025, 75 billion IoT devices will be connected with a potential market value of around $1.6 trillion. This not only brings unprecedented business opportunities, but also challenges such as how to streamline supply chain logistics for smart devices.

The solution simplifies manufacturing processes and logistics : In fact, device manufacturers no longer need to produce multiple product variants for deployment with different Mobile Network Operators (MNOs) in different countries. One product now fits all MNO networks as the IoT eSIM embedded in the industrial device can connect to any MNO network worldwide.

Thales system shortens device installation: Thanks to a remote activation process, the IoT eSIM automatically downloads the MNO profile that best suits the device location and connects to the network according to the service providers’ pre-defined business rules.

The solution guarantees network resilience and longevity : As networks and IoT applications evolve, the solution ensures reliable connectivity and business continuity by automatically switching to back-up connectivity providers removing the need for physical device updates.

“Thales leverages its unique expertise of cellular network infrastructure and collaboration with more than 400 mobile operators to simplify industrial IoT connectivity.The Thales Connectivity solution offers all the benefits of digitalisation and eSIM technology for the industrial IoT sector. With more than 25 years of constant innovation in IoT connectivity solutions, Thales enables the best total-cost-of-ownership and performance to its customers.” Frederic Deman, SVP of Analytics and IoT Solutions Business Line, at Thales.

“The IoT eSIM solution is a huge step forward for Aidon helping to ensure production flexibility and connectivity of our smart meters, even in rural areas, and all without the need for physical handling of SIMs,” said Petri Ounila, Director, IoT Devices, Aidon. “The solution co-developed with Thales provides a true operator selection and provisioning at any stage of the product lifetime. It is improving our ability to get smart meters connected, stay connected and adapt to new metering as-a-service business models.”

“The Thales Cinterion Connectivity Activation solution turns traditional methods of IoT device service provisioning and updating on its head, bringing new levels of service digitization, automation, Over-the-Air (OTA) management, and digital security to industrial IoT solutions” said Phil Sealy, Research Director at ABI Research . “Device manufacturers and service providers will no longer be tied to complex connectivity device design and logistics, thanks to a simplified and flexible approach. By easing the path to cellular connectivity and management, device manufacturers and service providers can redshift their focus toward innovation and scaling digital transformation for their customers.”

To learn more, join one of our virtual launch events on June 16 at 9:00 AM or 5:00 PM CEST.

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.

Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.

PLEASE VISIT

Thales Group
Digital Identity & Security page

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye